Next Article in Journal
Altered Promoter and G-Box Binding Factor for 1-Deoxy-d-Xylulose-5-Phosphate Synthase Gene Grown from Poa pratensis Seeds after Spaceflight
Next Article in Special Issue
Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
Previous Article in Journal
Kinetics of Physiological and Behavioural Responses in Endotoxemic Pigs with or without Dexamethasone Treatment
Previous Article in Special Issue
Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib
Review

Antigen Targets for the Development of Immunotherapies in Leukemia

1
Department of Hematology and Oncology, University Hospital Tübingen, 72076 Tübingen, Germany
2
Institute for Cell Biology, Department of Immunology, University of Tübingen, 72076 Tübingen, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(6), 1397; https://doi.org/10.3390/ijms20061397
Received: 26 February 2019 / Revised: 15 March 2019 / Accepted: 18 March 2019 / Published: 20 March 2019
(This article belongs to the Special Issue Advances in Molecular Biology and Targeted Therapy of Leukemias)
Immunotherapeutic approaches, including allogeneic stem cell transplantation and donor lymphocyte infusion, have significantly improved the prognosis of leukemia patients. Further efforts are now focusing on the development of immunotherapies that are able to target leukemic cells more specifically, comprising monoclonal antibodies, chimeric antigen receptor (CAR) T cells, and dendritic cell- or peptide-based vaccination strategies. One main prerequisite for such antigen-specific approaches is the selection of suitable target structures on leukemic cells. In general, the targets for anti-cancer immunotherapies can be divided into two groups: (1) T-cell epitopes relying on the presentation of peptides via human leukocyte antigen (HLA) molecules and (2) surface structures, which are HLA-independently expressed on cancer cells. This review discusses the most promising tumor antigens as well as the underlying discovery and selection strategies for the development of anti-leukemia immunotherapies. View Full-Text
Keywords: leukemia; immunotherapy; antigen; target; HLA; epitope; peptide; vaccination; T cell leukemia; immunotherapy; antigen; target; HLA; epitope; peptide; vaccination; T cell
Show Figures

Figure 1

MDPI and ACS Style

Bauer, J.; Nelde, A.; Bilich, T.; Walz, J.S. Antigen Targets for the Development of Immunotherapies in Leukemia. Int. J. Mol. Sci. 2019, 20, 1397. https://doi.org/10.3390/ijms20061397

AMA Style

Bauer J, Nelde A, Bilich T, Walz JS. Antigen Targets for the Development of Immunotherapies in Leukemia. International Journal of Molecular Sciences. 2019; 20(6):1397. https://doi.org/10.3390/ijms20061397

Chicago/Turabian Style

Bauer, Jens, Annika Nelde, Tatjana Bilich, and Juliane S. Walz. 2019. "Antigen Targets for the Development of Immunotherapies in Leukemia" International Journal of Molecular Sciences 20, no. 6: 1397. https://doi.org/10.3390/ijms20061397

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop